Neuroscience-focused biopharmaceutical company Neurocrine Biosciences Inc (Nasdaq:NBIX) on Tuesday announced a new chapter in its research and development strategy aimed at accelerating the company's next era for growth and delivering long-term value.

Neurocrine says that it is advancing a diversified pipeline of first- and best-in-class medicines across therapeutic modalities including two Phase 3 programmes, osavampator for major depressive disorder and direclidine for schizophrenia. Its clinical portfolio includes a pipeline of early- to mid-stage muscarinic agonists and VMAT2 inhibitors for the treatment of neuropsychiatric indications, and CRF-based therapies for metabolic diseases, including obesity.

By the end of the decade, Neurocrine expects its R&D engine to deliver an approved medicine every two years.